Advertisement

Topics

FDA backs Veru's study of drug for treatment-resistant prostate cancer

06:15 EDT 13 Sep 2018 | SmartBrief

Veru has received agreement from the FDA for its planned Phase I/II study to assess VERU-111 in patients with metastatic cast -More

Original Article: FDA backs Veru's study of drug for treatment-resistant prostate cancer

NEXT ARTICLE

More From BioPortfolio on "FDA backs Veru's study of drug for treatment-resistant prostate cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...